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The recent, and rapid, emergence of injection of the 
short-acting stimulant mephedrone (4-methylmeth-
cathione) has resulted in concerns about increased 
infection risks among people who inject drugs (PWID). 
Data from the bio-behavioural surveillance of PWID 
in the United Kingdom were analysed to examine the 
impact of mephedrone injection on infections among 
PWID. During the year preceding the survey, 8.0% of 
PWID (163/2,047) had injected mephedrone. In multi-
variable analyses, those injecting mephedrone were 
younger, less likely to have injected opiates, and more 
likely to have injected cocaine or amphetamines, used 
needle/syringe programmes or sexual health clin-
ics, been recruited in Wales and Northern Ireland or 
shared needles/syringes. There were no differences 
in sexual risks. Those injecting mephedrone more 
often had hepatitis C antibodies (adjusted odds ratio 
(AOR) = 1.51; 95% confidence interval (CI): 1.08–2.12), 
human immunodeficiency virus (AOR = 5.43; 95% CI: 
1.90–15.5) and overdosed (AOR = 1.70; 95% CI: 1.12–
2.57). There were no differences in the frequency of 
injecting site infections or prevalence of hepatitis B. 
The elevated levels of risk and infections are a con-
cern considering its recent emergence. Mephedrone 
injection may currently be focused among higher-risk 
or more vulnerable groups. Targeted responses are 
needed to prevent an increase in harm.
Introduction
Over the past decade, the emergence of the use of 
‘new psychoactive substances’ has caused major con-
cerns in many countries [1,2]. New psychoactive sub-
stances encompass a range of synthetic substances, 
including synthetic cannabinoids, cathinones, pipera-
zines, tryptamines and phenethylamines, that are not 
controlled by two United Nations Conventions (the 1961 
Convention on Narcotic Drugs and the 1971 Convention 
on Psychotropic Substances), but which may pose a 
public health threat that is comparable to that of the 
substances listed in these conventions [3]. The use of 
synthetic cathinones, and especially drugs marketed 
as mephedrone have caused particular concern in a 
number of countries including the United Kingdom (UK) 
[3-6].
Mephedrone is the common name for 4-methylmeth-
cathione, it is a relatively short-acting stimulant with 
reported effects similar to amphetamine and MDMA 
[5,7]. It can be administered in a variety of ways, 
including snorting, ingestion and injection, and com-
pulsive re-dosing over a period of many hours has been 
reported, due to rapid comedown when snorted or 
induced tolerance when injected repeatedly [5,8]. The 
use of drugs marketed as ‘mephedrone’ under street 
names such as ‘drone’, ‘m-cat’ and ‘meow meow’, have 
increased since its use was first reported around 2007. 
The subsequent emergence of the injection of syn-
thetic cathinones, including mephedrone, has caused 
particular concerns in Europe [9], with the injection of 
these drugs having been associated with increases in 
human immunodeficiency virus (HIV) infections and 
risk behaviours among people who inject drugs (PWID) 
in several central European countries [10,11]. The use, 
and in particular the injection, of mephedrone by some 
populations of men who have sex with men (MSM), par-
ticularly during sex, has also recently been reported in 
Europe and elsewhere [12-14], often in settings where 
unsafe sex and sharing of injecting equipment occur 
[12,13].
In the UK, the use of mephedrone was first noted in 
2008 [15,16], leading to 4-methylmethcathione being 
2 www.eurosurveillance.org
Figure
Variations in the extent of mephedrone injecting, by age, time in years since first injection, region of recruitment, and 
sexual activity, United Kingdom, 2013 (n = 2,047)
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B. Years since first injected (n=1,989) D. Sexual activity (n=2,047)
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controlled under the Misuse of Drugs Act in 2010 [17]. 
The injection of this drug is a more recent practice that 
was first reported in the UK in 2012; it occurred among 
people who had switched from snorting as well as 
among people who had previously injected other drugs 
including opioids and stimulants [18]. Of particular con-
cern is the compulsion to re-dose when using mephe-
drone, increasing the frequency of injecting from two 
or three times daily to 15–20 times, raising the risk of 
injecting site damage and of infection through poor 
injection hygiene and the reuse and sharing of inject-
ing equipment [19].
In response to the emergence of mephedrone injecting 
and the associated concerns about the risks, mephed-
rone was added to the list of drugs specifically asked 
about in the UK’s national bio-behavioural surveillance 
system of infections and risks among PWID in 2013. 
In this paper, we used data from this large national 
survey to (i) assess the current extent of mephedrone 
injecting in the UK, (ii) examine the factors associated 
with mephedrone injecting and (iii) describe the fre-
quency of a range of health harms among those inject-
ing mephedrone.
Methods
PWID have been recruited into a voluntary unlinked 
anonymous monitoring system in the UK since 1990; 
methodological details of this series of annual cross-
sectional surveys have been published previously 
[20,21]. Briefly, agencies providing services to PWID 
(e.g. needle and syringe programmes (NSPs) and pro-
viders of addiction services such as opiate substitu-
tion therapy (OST)) at sentinel locations (n = 67 in 2013) 
throughout the UK except Scotland, invite clients who 
have ever injected psychoactive drugs to participate in 
the survey each year. The sentinel sites are selected 
so as to reflect both the geographical distribution and 
range of services offered to PWID. Those who consent 
to participate provide a biological sample, currently 
a dried blood spot (DBS), and self-complete a brief 
questionnaire focused on the injection of psychoactive 
drugs. In 2013, the answer categories to the question 
asking about the drugs injected during the preceding 
year was revised to include a new response category: 
‘mephedrone (m-cat)’. The survey has multi-site ethics 
approval.
The DBS specimens were tested for antibodies to HIV 
(anti-HIV), the hepatitis B core antigen (anti-HBc) and 
hepatitis C virus (anti-HCV). The anti-HIV test was an 
in-house IgG capture enzyme-linked immunosorbent 
assay (GACELISA) with similar performance to the HIV 
1+2 GACELISA (Abbott Murex Diagnostics Ltd, Dartford, 
UK). Reactive specimens underwent further testing 
according to an algorithm that included a second ELISA 
and Western blot [22]. Anti-HCV testing employed a 
previously validated commercial enzyme-immunoassay 
(Ortho HCV 3.0 SAVe, Ortho Diagnostics, New Jersey) 
[23]. For hepatitis C, a previously described algorithm 
using antibody avidity testing was applied to the survey 
samples to identify probable recent hepatitis C infec-
tions, i.e. samples with weak antibody avidity < 40% in 
the presence of HCV RNA [24]. For anti-HBc, an in-house 
IgG class-specific antibody capture enzyme immunoas-
say (EIA) was used. 
For those who had injected during the preceding year, 
bivariate associations (p < 0.05) between the outcome 
variable, i.e. having injected mephedrone, and covari-
ates (demographics, injecting practices, drugs injected, 
sexual practice and use of health services) were exam-
ined using Pearson’s chi-squared test. Where possible 
associations were found (p < 0.10), these were further 
examined via logistic regression using the forward 
stepwise procedure to select variables for inclusion 
in the model, with selection based on the likelihood 
ratio test (p < 0.05). All analyses were undertaken using 
SPSS 19.
Associations between mephedrone injecting and a 
range of health harms were explored by examining 
the frequency of mephedrone injecting among those 
with and without harms (anti-HIV, anti-HBc, anti-HCV, 
reported recent symptoms of injection site infections 
or injuries, and reported recent overdose). Data were 
adjusted for age, sex and region as these factors are 
known to be associated with these harms [20,21,25,26].
Results
Sample characteristics
During 2013, the survey recruited 2,047 individuals 
who had injected psychoactive drugs during the pre-
ceding year. Almost half (47%; n = 953) were aged 35 
years or older (mean age: 36 years, median: 35 years), 
26% (n = 522) were women and 5% (n = 107) had been 
born outside of the UK. Almost one fifth, 18% (n = 369), 
reported that they had been homeless during the pre-
ceding year and almost three quarters, 72% (n = 1,471), 
reported that they had ever been imprisoned.
The majority, 85% (n = 1,733), reported using an NSP 
service during the preceding year and 69% (n = 1,418) 
were currently in receipt of a maintenance drug regime 
such as OST or on detoxification. During the year pre-
ceding the survey, 10% (n = 204) had visited a sexual 
health (genito-urinary medicine) clinic, 20% (n = 411) a 
walk-in (minor injury/primary care) clinic, 30% (n = 617) 
an Emergency Department and 65% (n = 1,331) a gen-
eral practitioner. Overall, 75% (n = 1,531) had ever had 
a voluntary confidential test for HIV, 81% (n = 1,667) for 
hepatitis C, and 72% (n =  1,471) had received at least 
one dose of hepatitis B vaccine.
Drugs injected and injecting risks
The most commonly injected drug during the year pre-
ceding the survey was heroin (92%; n = 1,879). Two-
fifths reported that they had injected crack cocaine 
(43%; n = 885), almost three-tenths had injected 
amphetamines (29%; n = 591) and just over one-tenth 
had injected powder cocaine (12%; n = 245). Injecting 
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Table 1
Factors associated with injecting mephedrone during the preceding year among people who inject drugs, United Kingdom, 
2013 (n = 2,047)
Characteristica Injected mephedrone in the preceding year?
Yes
Total p value
Odds 
ratio   95% CI  
Adjusted 
odds ratio   95% CI  % n
All 8.0 163 2,047 NA
Demographic characteristics
Age
< 25 years 19 28 144
<0.001 NA 
25–34 years 9.3 75 809
35–44 years 6.5 53 811
≥ 45 years 2.5 7 283
Per year increase in age 0.94 0.92–0.96 0.95 0.92–0.97 
Number of years since first 
injected
< 5 years 12 41 356
0.003
1.00 Ref
b 
5–9 years 10 36 349 0.88 0.55–1.42
10–14 years 8.5 35 413 0.71 0.44–1.14
15–19 years 5.4 23 429 0.44 0.26–0.74 
≥ 20 years 6.1 27 442 0.50 0.30–0.83 
Not known 1.7 1 58 0.13 0.02–1.00
Region/Country
Midlands and Eastern 
England 7.2 46 640
<0.001
1.00 Ref 1.00 Ref
London and Southern 
England 4.2 24 567 0.57 0.34–0.95 0.60 0.35–1.02
Northern England 7.5 46 613 1.05 0.69–1.60 0.91 0.58–1.43
Wales and Northern Ireland 21 47 227 3.37 2.17–5.23 3.06 1.91–4.89 
Homeless preceding year
Not last year/never 7.4 125 1,678
0.067
1.00 Ref
b 
Yes last year 10 38 369 1.43 0.97–2.09
Anal or vaginal sex during 
preceding year
Men who had sex with men 8.2 7 85
0.017
1.64 0.70–3.84
b 
Men who had sex with 
women only 9.7 90 931 1.95 1.29–2.96 
Women who had sex with 
men and/or women c 8.2 34 415 1.63 0.99–2.68
Not had sex (men and 
women) 5.2 32 616 1.00 Ref
Injecting practice during the preceding year
Injected heroin
No 21 35 168
<0.001
1.00 Ref 1.00 Ref
Yes 6.8 128 1,879 0.28 0.18–0.42 0.35 0.22–0.56 
Injected amphetamine 
(speed)
No 4.7 68 1,456
<0.001
1.00 Ref 1.00 Ref
Yes 16 95 591 3.91 2.82–5.43 2.42 1.68–3.50 
Injected cocaine
No 6.8 123 1,802
<0.001
1.00 Ref 1.00 Ref
Yes 16 40 245 2.66 1.81–3.91 2.36 1.53–3.63 
Used needles or syringes 
previously used by 
someone else
No 6.8 117 1,729
<0.001
1.00 Ref 1.00 Ref
Yes 14 46 318 2.33 1.62–3.35 1.95 1.31–2.92 
Health services usage
Used needle and syringe 
programme preceding year
Not last year /Never 4.8 15 314
0.023
1.00 Ref 1.00 Ref
Last year 8.5 148 1,733 1.86 1.08–3.21 1.89 1.04–3.42 
Prescribed opiate 
substitution therapy
Previously/Never 10 63 629
0.016
1.00 Ref
b 
Currently 7.0 99 1,418 0.67 0.48–0.93 
Used sexual health 
(genito-urinary medicine) 
clinic preceding year
No 6.9 114 1,649
<0.001
1.00 Ref 1.00 Ref
Yes 17 35 204 2.79 1.85–4.20 2.10 1.32–3.35 
Not known 7.2 14 194 1.05 0.59–1.86 0.99 0.54–1.82
CI: confidence interval; NA: not applicable; Ref: reference value.
a No associations with: sex; being born in the United Kingdom, ever being imprisoned, injecting crack during the preceding 12 months, using a 
walk-in (minor injury/primary care) clinic during the preceding 12 months, using an emergency department during the preceding 12 months, 
visiting a general practitioner during the preceding 12 months, ever having had a voluntary confidential test for human immunodeficiency 
virus, ever having had a voluntary confidential test for hepatitis C, and uptake of vaccine against hepatitis B.
b Entered in multivariate analyses but not in the final model.
c The number of women reporting sex with women was small (< 50) and they are thus not reported separately.
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mephedrone during the preceding year was reported 
by 8% (n = 163) of participants. Overall, 41% (n = 847) 
of the participants reported injecting only one of these 
five drugs during the preceding year and 19% (n = 391) 
reported injecting three or more of them. Those report-
ing that they had injected mephedrone were more likely 
to report injecting three or more of the other four drugs 
(63% (n = 102) vs 15% (n = 289); p < 0.001). Of those 
who reported injecting mephedrone, 13% (n = 21) had 
also injected all of the other four drugs (i.e. heroin, 
crack cocaine, amphetamines and powder cocaine); 
8% (n = 13) had not injected any of these four other 
drugs.
Those injecting mephedrone were younger (mean age: 
32 years, median: 31 years vs mean age: 36 years, 
median: 35 years; p < 0.001), had been injecting for 
fewer years (mean duration: 11 years, median: 10.5 
years vs mean duration: 14 years, median: 13 years; 
p = 0.001), and were more likely to be living in Wales 
or Northern Ireland (p < 0.001, the level of use was very 
similar in both of these areas) (Figure). Overall, 16% 
(n = 318) of all of the participants reported that they 
had knowingly receptively shared needles or syringes 
(i.e. injected with needles or syringes that had previ-
ously been used by someone else) during the preced-
ing year. Reporting sharing was more common among 
those injecting mephedrone than those not (28%; 
n = 46 vs 14%; n = 272; p < 0.001). Similarly, those 
injecting mephedrone were more likely to report having 
ever receptively shared a needle or syringe (59%; n = 
96 vs 46%; n = 864; p = 0.001).
Sexual risk and condom use
The majority of all survey participants were sexu-
ally active, with just over two-thirds (70%; n = 1,431) 
reporting that they had had anal or vaginal sex in the 
preceding year; 5.6% (n = 85) of the men reported sex 
with other men. Heterosexual men were more likely 
to report injecting mephedrone than MSM or women 
(p = 0.017, Figure). Of those sexually active, 35% 
(n = 503) reported having two or more sexual partners 
during the preceding year overall; 53% (n = 45) of the 
MSM had two or more partners, 37% (n = 348) of het-
erosexual men, and 27% (n = 110) of the women (who 
either had sex with men and/or women, there were < 50 
women reporting female partners). Of those with two 
or more partners, 17% (n = 84) reported always using 
condoms; 13% (n = 6) of the MSM, 17% (n = 59) of 
heterosexual men, and 17% (n = 19) of the women. 
Mephedrone injection was not associated with the 
extent of condom use among those with two or more 
sexual partners.
Factors associated with mephedrone injecting
The bivariate and multivariable associations are shown 
in Table 1. In the multivariable analysis, mephed-
rone injecting during the preceding year was associ-
ated with younger age. It was more common in Wales 
and Northern Ireland, among those who had injected 
amphetamine or powder cocaine, those who had 
shared needles or syringes, those using NSPs or sex-
ual health (genito-urinary medicine) clinics. It was less 
common among those who had injected heroin.
Health harms and mephedrone injecting
Testing of the DBS samples collected in the survey 
found that overall, 1.1% (n = 23) of the participants had 
anti-HIV, 15% (n = 311) anti-HBc, and 50% (n = 1,027) 
anti-HCV. Having had an abscess, sore or open wound 
at an injection site during the preceding year was 
reported by 25% (n = 502) of the participants, and an 
overdose during the preceding year was reported by 
14% (n = 277). After adjustment, injecting mephedrone 
was found to be more common among those with anti-
HIV or anti-HCV, and among those reporting an over-
dose during the preceding year (Table 2).
Those who reported that they had ever had a voluntary 
confidential test for HIV or hepatitis C were also asked 
about the result of their last test. These data were used 
to assess the proportion of those with anti-HIV and 
anti-HCV who were aware of their infections. Of those 
anti-HCV-positive, it was possible to assess awareness 
for 87% (n = 898); of these, 46% (n = 417) were aware 
of their infection and awareness was similar among 
those injecting mephedrone and those not (43% vs 
47%, p = 0.393). Among those with HIV, it was possible 
to assess awareness for 87% (n = 20); of these, 95% 
(n = 19) were aware of their infection and again there 
was no difference in awareness between those inject-
ing and those not injecting mephedrone (100% vs 94% 
respectively, p=1.000, Fisher's exact test).
A laboratory testing algorithm was applied to the sam-
ples collected in the survey to identify probable recent 
infections with HCV [24], i.e. those with weak anti-HCV 
avidity in the presence of HCV RNA. This algorithm 
identified 28 probable recent infections among those 
participants who had been at risk of hepatitis C infec-
tion (n = 1,048); thus overall, 2.7% of those who had 
been at risk had recently become infected with HCV. 
There was no difference in the extent of these probable 
recent infections between those who reported inject-
ing mephedrone and those who did not (2.5% vs 2.7% 
respectively, p = 0.936).
Discussion
Considering the recent, and rapid, emergence of the 
injection of mephedrone, the elevated levels of risk 
and harm found in our study among those who had 
injected mephedrone are a concern. Within two years 
of mephedrone injection first being reported in the UK 
it was being injected by one in 12 PWID. Worryingly, 
those with HIV were more than five times as likely to 
report mephedrone injecting, and mephedrone inject-
ing was also more common among those with anti-
bodies to HCV and those who had recently overdosed. 
Although there were no differences in sexual risk, 
injecting risks were significantly higher among those 
injecting mephedrone.
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Our findings suggest the spread of mephedrone inject-
ing within the UK has been fairly rapid since this was 
first reported in 2012. The rapid emergence of the injec-
tion of synthetic cathinones, often as substitute for or 
in addition to other drugs, has also been reported in 
several central European countries [9-11]. However, the 
extent of mephedrone injecting varied markedly across 
the UK, from around one in 25 in London and the south 
of England, through around one in 14 elsewhere in 
England, to one in five in both Wales and Northern 
Ireland. This indicates that the emergence of mephe-
drone injecting in both Wales and Northern Ireland 
has been more extensive and rapid than in England. 
The reasons for these geographical differences are 
unknown and further research is required to explore 
this.
Mephedrone injecting was more common among those 
who reported injecting other stimulants (amphetamine 
and powder cocaine) and was less common among 
those injecting heroin. This is perhaps to be expected 
given that mephedrone is also a stimulant. This find-
ing suggests that the emergence of mephedrone inject-
ing might, in part at least, be driven by issues such as 
drug availability, price and/or drug purity, leading to 
drug substitution among existing populations of peo-
ple who inject stimulants [27]. As opiate injecting has 
most probably declined in the UK [28], particularly in 
England [29], and is now focused in an ageing cohort 
[30], the emergence of mephedrone injecting may also 
be part of a generational shift towards the injection 
of stimulants [31]. Those who had injected mephed-
rone were overall younger and had been injecting for 
a shorter time than those who had only injected other 
drugs. Considering this, and that a small number of 
those sampled reported injecting only mephedrone, it 
is possible that a new group of PWID who inject mephe-
drone, either alone or in conjunction with other drugs, 
might be emerging [18]. These findings thus indicate 
that currently mephedrone injecting is mostly occurring 
among existing populations of PWID, but they also sug-
gest the emergence of a new group of younger PWID 
with potentially higher risks.
Those reporting mephedrone injection were twice as 
likely to report sharing injecting equipment, indicat-
ing that they are a high risk group. This is supported 
by the higher HIV and hepatitis C prevalence and 
overdoses being more common among those inject-
ing mephedrone. The data on the proportions aware 
of their infection with HIV or hepatitis C indicate that 
awareness does not vary between those injecting and 
those not injecting mephedrone, which suggests that 
there might be no difference in the recency of these 
infections (recent infections are probably less likely to 
have been diagnosed than longer standing ones). This 
is corroborated by our data on probable recent HCV 
infections, which indicate that there is no difference in 
the incidence of HCV infection between those injecting 
mephedrone and those not injecting mephedrone. Our 
findings thus suggest that mephedrone injection in the 
UK is currently mainly concentrated among groups of 
PWID that already have elevated levels of risk, infec-
tion and harm.
Table 2
Health harms and extent of mephedrone injecting among people who inject drugs, United Kingdom, 2013 (n = 2,047)
Injected mephedrone during the preceding year? Had harm n p value Odds ratio (95% CI)
Adjusted odds 
ratio (95% CI)
a
Had an abscess, sore or open wound during preceding year 
Not injected mephedrone 24% 461 1,884
0.846
1.00 Ref 1.00 Ref
Injected mephedrone 25% 41 163 1.04 0.72–1.50 1.10 0.75–1.62
Had antibodies to hepatitis C 
Not injected mephedrone 50% 941 1,884
0.491
1.00 Ref 1.00 Ref
Injected mephedrone 53% 86 163 1.12 0.81–1.54 1.51 1.08–2.12
Had antibodies to hepatitis B core antigen 
Not injected mephedrone 16% 298 1,884
0.007 
1.00 Ref 1.00 Ref
Injected mephedrone 8.0% 13 163 0.46 0.26–0.82 0.73 0.40–1.33
Had antibodies to HIV 
Not injected mephedrone 1.0% 18 1,884
0.014 
1.00 Ref 1.00 Ref
Injected mephedrone 3.1% 5 163 3.28 1.20–8.95 5.43 1.90–15.5
Had an overdose during preceding year 
Not injected mephedrone 13% 243 1,884
0.004 
1.00 Ref 1.00 Ref
Injected mephedrone 21% 34 163 1.78 1.19–2.66 1.70 1.12–2.57
CI: confidence interval; HIV: human immunodeficiency virus; Ref: reference value.
a Adjusted for age, sex and region/country as these factors are known to be associated with the outcomes.
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Considering the higher levels of injecting risk behav-
iours and infections among those injecting mephe-
drone, our findings indicate that the emergence of 
mephedrone injection in the UK has the potential to 
increase the transmission of infections among PWID, 
particularly if its use is sustained or becomes more 
widespread. The rapid emergence of the injection of 
synthetic cathinones has already been implicated in 
increases in viral hepatitis and HIV transmission in a 
number of other European countries [10,11,32].
Mephedrone injection was not associated with 
increased sexual risk in our study, although it was 
more commonly reported among those who were sex-
ually active and younger. However, overall levels of 
unsafe sexual practice were high. Mephedrone use and 
injecting has been associated with sexual risk in some 
populations, specifically subgroups of MSM where 
it has been linked to high risk behaviours and infec-
tions [12,13,33,34], and mephedrone use has also been 
reported to have positive effects on libido [35]. Those 
injecting mephedrone in our study were more likely 
to have used a sexual health service, suggesting that 
mephedrone injection may be related to increased sex-
ual health needs that may not have been detected by 
the limited data on sexual behaviour collected in our 
study, and further investigation is required.
The findings presented here suggest that interven-
tions are needed to address mephedrone injec-
tion. Responses should first look at ways to improve 
injection practice and hygiene, as well as promoting 
awareness among PWID of the risks and harms that 
are associated with injecting mephedrone [9,18,19]. 
However, to date, the UKs response to the injection of 
psychoactive drugs has had a strong focus on the tradi-
tional predominant drug, heroin, with an emphasis on a 
combination of high coverage NSPs and easy to access 
OST, which have been shown to be effective for reduc-
ing infections [36]. Although stimulant injection is not 
a new phenomenon in the UK, this has predominantly 
been in the form of crack cocaine injection alongside 
heroin (both need to be dissolved in acidic solutions), 
whereas the injection of amphetamines has been com-
paratively rare but may have increased in recent years 
[31]. With the emergence of mephedrone injection, 
responses will need to adapt to the increased use of 
water-soluble drugs and make greater use of treat-
ments that are appropriate for users of stimulant drugs 
[37]. There may also be a need to explore the provision 
of these services in non-traditional settings, such as 
community-based outreach services and sexual health 
clinics.
This study has a number of potential limitations. 
Firstly, the illicit and marginalised nature of injecting 
drug use makes the recruitment of a representative 
sample problematic. To maximise representativeness, 
this survey used an accepted approach for surveillance 
surveys involving recruitment at multiple sites through 
targeted services for PWID as a sampling frame [38,39]. 
In the UK, there is extensive provision of such targeted 
services, and the uptake and use of these is high, with 
very few of the PWID recruited through community-
based studies found not to be in contact with these 
services [40]. For emerging drugs such as mephedrone, 
there may be new groups of users or populations where 
new patterns of injecting have emerged, such as some 
sub-groups of MSM. These groups may be less likely to 
be in contact with services or have different patterns 
of service use. This may possibly lead to such users 
being under-represented. Secondly, the behavioural 
data used here are based on self-reports, the accuracy 
of which may be subject to recall bias; however, the 
reliability of self-reported risk behaviours among PWID 
has been shown in other studies [41,42]. Considering 
these issues, the findings presented here should be 
generalised with caution.
Conclusion
Although the associations found here need further 
investigation, they suggest that the injection of mephe-
drone may be focused among younger and higher-risk 
groups of PWID, who may be particularly vulnerable to 
harm. Most of those injecting mephedrone were also 
using other drugs; however, a number were not. These 
findings, together with the younger age of those inject-
ing mephedrone, suggest that new groups of PWID 
may also be emerging. Services in contact with PWID, 
including NSPs and sexual health clinics, will need to 
be alert to these elevated infection risks and the harm 
reduction needs of those injecting mephedrone. In the 
UK, the level of reported needle and syringe sharing 
among PWID is currently stable and lower than it was 
a decade ago, while the overall prevalences of HIV and 
hepatitis C among PWID have changed little in recent 
years; targeted responses, such as risk reduction inter-
ventions for those injecting mephedrone, are therefore 
needed to prevent an increase in the transmission of 
infections among PWID. Considering the increasing 
range of new psychoactive substances [43], vigilance 
should also be maintained for possible emergence 
other injected substances.
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